| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From Alzheimer Disease Research Center, UCLA Department of Neurology (J.M.R., G.M.C., D.H.G., B.S., L.D.M., J.L.C.), School of Nursing (J.F., S.S., K.H.G.), and Department of Medicine (E.R.R.), University of California, Los Angeles; Department of Pharmacology (S.G.Y.), Mayo Clinic, Jacksonville, FL; Department of Pharmacology (D.P.), Temple University, Philadelphia, PA; Athena Diagnostics, Inc. (W.S.), Worcester, MA; Greater Los Angeles Veterans Affairs Geriatric Research (G.M.C.), Education, and Clinical Center; National Institute of Neurology and Neurosurgery (Y.R.-A.), Mexico City, Mexico; and Department of Neurology (A.V.), Keck School of Medicine, USC, Rancho Los Amigos National Rehabilitation Center, Downey, CA.
* To whom correspondence should be addressed. E-mail: jringman{at}mednet.ucla.edu.
Background: Persons at risk for familial Alzheimer disease (FAD) provide a model in which biomarkers can be studied in presymptomatic disease.
Methods: Twenty-one subjects at risk for presenilin-1 (n = 17) or amyloid precursor protein (n = 4) mutations underwent evaluation with the Clinical Dementia Rating (CDR) scale. We obtained plasma from all subjects and CSF from 11. Plasma (A
40, A42, F2-isoprostanes) and CSF (F2-isoprostanes, t-tau, p-tau181, A40, A42, and A42/A40 ratio) levels were compared between FAD mutation carriers (MCs) and noncarriers (NCs).
Results: Plasma A42 levels (25.1 pM vs 15.5 pM, p = 0.031) and the ratio of A42/A40 (0.16 vs 0.11, p = 0.045) were higher in presymptomatic MCs. Among MCs, those with CDR scores of 0.5 had lower plasma A42 levels than those with CDR scores of 0 (14.1 pM vs 25.1, p = 0.02). The ratio of A42 to A40 was also reduced in the CSF (0.08 vs 0.15, p = 0.046) of nondemented MCs compared to NCs. Total CSF tau and p-tau181 levels were elevated in presymptomatic FAD MCs. CSF levels of F2-isoprostanes were also elevated in MCs (n = 7, 48.6 pg/mL) compared to NCs (n = 4, 21.6 pg/mL, p = 0.031).
Conclusions: Our data indicate that A42 is elevated in plasma in familial Alzheimer disease (FAD) mutation carriers (MCs) and suggests that this level may decrease with disease progression prior to the development of overt dementia. We also demonstrated that the ratio of A42 to A40 was reduced in the CSF of nondemented MCs and that elevations of t-tau and p-tau181 are sensitive indicators of presymptomatic disease. Our finding of elevated F2-isoprostane levels in the CSF of preclinical FAD MCs suggests that oxidative stress occurs downstream to mismetabolism of amyloid precursor protein.
This article has been cited by other articles:
|
|
 |
|
  M. Dumont, E. Wille, C. Stack, N. Y. Calingasan, M. F. Beal, and M. T. Lin Reduction of oxidative stress, amyloid deposition, and memory deficit by manganese superoxide dismutase overexpression in a transgenic mouse model of Alzheimer's disease FASEB J, August 1, 2009; 23(8): 2459 - 2466. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Xia, T. Yang, G. Shankar, I. M. Smith, Y. Shen, D. M. Walsh, and D. J. Selkoe A Specific Enzyme-Linked Immunosorbent Assay for Measuring {beta}-Amyloid Protein Oligomers in Human Plasma and Brain Tissue of Patients With Alzheimer Disease Arch Neurol, February 1, 2009; 66(2): 190 - 199. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Quinn and M. N. Sabbagh Detecting Alzheimer disease before it happens: The key to prevention? Neurology, July 8, 2008; 71(2): 78 - 79. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
